Jakafi and Metastases to lymph nodes - a phase IV clinical study of FDA data

Summary:

Metastases to lymph nodes is found among people who take Jakafi, especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Jakafi and have Metastases to lymph nodes. It is created by eHealthMe based on reports of 46,732 people who have side effects when taking Jakafi from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

46,732 people reported to have side effects when taking Jakafi.
Among them, 15 people (0.03%) have Metastases to lymph nodes.


What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 46,798 Jakafi users for its effectiveness, alternative drugs and more.

What is Metastases to lymph nodes?

Metastases to lymph nodes (cancer spreads to lymph node) is found to be associated with 1,162 drugs and 695 conditions by eHealthMe.

Number of Jakafi and Metastases to lymph nodes reports submitted per year:

Could Jakafi cause Metastases to lymph nodes?

Time on Jakafi when people have Metastases to lymph nodes *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 100 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Metastases to lymph nodes when taking Jakafi *:

  • female: 57.14 %
  • male: 42.86 %

Age of people who have Metastases to lymph nodes when taking Jakafi *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Jakafi *:

  1. Zofran: 6 people, 40.00%
  2. Calcium: 6 people, 40.00%
  3. Vitamin B6: 6 people, 40.00%
  4. Reglan: 6 people, 40.00%
  5. Keppra: 6 people, 40.00%
  6. Xarelto: 6 people, 40.00%
  7. Myrbetriq: 4 people, 26.67%
  8. Potassium: 2 people, 13.33%
  9. Vitamin D: 2 people, 13.33%
  10. Eliquis: 2 people, 13.33%

Common side effects people have besides Metastases to lymph nodes *:

  1. Swallowing Difficulty: 7 people, 46.67%
  2. Cough: 6 people, 40.00%
  3. Fall: 6 people, 40.00%
  4. Malaise (a feeling of general discomfort or uneasiness): 6 people, 40.00%
  5. Muscle Aches (muscle pain): 6 people, 40.00%
  6. Gastroenteritis Viral (inflammation of stomach and intestine caused by virus infection): 6 people, 40.00%
  7. Nausea (feeling of having an urge to vomit): 6 people, 40.00%
  8. Nausea And Vomiting: 6 people, 40.00%
  9. Gait Disturbance: 6 people, 40.00%
  10. Neuropathy Peripheral (surface nerve damage): 6 people, 40.00%

Common conditions people have *:

  1. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 11 people, 73.33%
  2. Splenomegaly (enlargement of spleen): 1 person, 6.67%
  3. Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 6.67%
  4. Joint Pain: 1 person, 6.67%
  5. Hypokalemia (low potassium): 1 person, 6.67%
  6. High Blood Pressure: 1 person, 6.67%
  7. High Blood Cholesterol: 1 person, 6.67%
  8. Fever: 1 person, 6.67%
  9. Diarrhea: 1 person, 6.67%
  10. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Metastases to lymph nodes?

Check whether Metastases to lymph nodes is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Metastases to lymph nodes and when was it recovered:

Expand to all the drugs that have ingredients of ruxolitinib phosphate:

Alternative drugs to, pros and cons of Jakafi:

Common Jakafi side effects:

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Metastases to lymph nodes treatments and more:

COVID vaccines that are related to Metastases to lymph nodes:

Common drugs associated with Metastases to lymph nodes:

All the drugs that are associated with Metastases to lymph nodes:

Common conditions associated with Metastases to lymph nodes:

All the conditions that are associated with Metastases to lymph nodes:

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: